Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity (Q33832519)

29 July 2017

1 reference

title

Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity (English)

1 reference

29 July 2017

1 reference

1 reference

Bastard JP

1

1 reference

29 July 2017

Piéroni L

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Biomedicine and Pharmacotherapy

29 July 2017

published in

1 reference

29 July 2017

volume

53

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

455-461

1 reference

Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Obesity, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Assessment of insulin sensitivity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Fibrin and Its Derivatives in the Normal and Diseased Vessel Wall

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Five Frequent Polymorphisms of the PAI-1 Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Mechanisms of physiological fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Atherogenic lipoproteins and release of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Hypertriglyceridemia and regulation of fibrinolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Pathophysiology of insulin resistance in human disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a))

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Atherosclerosis and the coagulation system

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2800%2988103-2

7 January 2021

10.1016/S0753-3322(00)88103-2

Identifiers

DOI

1 reference

29 July 2017

1 reference